)
)
)
Alphyn is developing first-in-class therapeutics for severe and prevalent skin diseases using its unique multiple bioactive Zabalafin Multi-Target Therapeutic Drug Platform. Zabalafin Hydrogel, the company's lead candidate for atopic dermatitis (AD), is at the forefront of an evolution to treat the bacterial cause and exacerbation of the disease, in addition to directly treating the itch, inflammation, and infection that make AD so difficult to manage. AD is a devastating chronic disease with with an estimated market size of $118 billion globally. Current treatments fall short on efficacy and safety for worry-free, long-term, and continuous use, and address only the immune component of the disease. Alphyn is well positioned with a differentiated product that addresses these shortcomings. After two Phase 2a clinical trials showing superiority to current commercial and investigational therapeutics, Zabalafin Hydrogel will begin global Phase 2b trials this year.
Year Founded
2020 (operational)
Next catalyst (value inflection) update
Phase 2b results
Expected time of next catalyst update
01/12/2025
City
Annapolis
Country
United States
Company CEO or top company official
Neal Koller
Development Phase of Primary Product
Phase II
Lead Product in Development
Zabalafin Hydrogel (ZH), is a topical in development to treat atopic dermatitis (AD), the most common form of eczema. ZH has completed two Phase 2a clinical with results that show superiority to recently approved and clinical-stage AD drugs, as well the best side effect and patient tolerability profile for potential long-term, worry-free, continuous use. ZH is unique with multiple active compounds to treat the multiple problems of AD, specifically directly treating AD itch, directly treating the bacteria that cause AD inflammation, and directly treating AD inflammation.
Number of Unlicensed Products
1
Therapeutic Area
Dermatology
Website
http://www.alphynbiologics.com